Novartis AG
COMBINATIONS COMPRISING FXR AGONISTS
Last updated:
Abstract:
The invention provides pharmaceutical compositions comprising a farnesoid X receptor (FXR) agonist or caspase inhibitor and another therapeutic agent, e.g.. PPAR-delta agonist in particular for treating or preventing liver diseases or disorders.
Status:
Application
Type:
Utility
Filling date:
11 Sep 2018
Issue date:
3 Sep 2020